Simulate first, then a human deploys. LIFE OS never deploys on its own.
Interventions
Synthetic demo data
What is working in this population
Outcomes of every action among the 204 patients matching “eligible for HY-01”. Sorted by evidence weight (n × improved share).
| Action | n | Improved | Mean effect | Onset | |
|---|---|---|---|---|---|
| GI-04 GI Support Protocol | 108 | 70% | −19% | 8 d | Simulate |
| ME-01 Monitoring Escalation | 70 | 100% | −3% | 3 d | Simulate |
| NP-02 Dietary Support Protocol | 56 | 59% | −14% | 10 d | Simulate |
| SC-12 Supportive Compound | 43 | 72% | −15% | 6 d | Simulate |
| CR-01 Clinician Review | 7 | 100% | −14% | 5 d | Simulate |
Create intervention
- Cohort
- 204 patients · eligible for HY-01
Enforcement in the companion
Before deployment
simulationCampaigns
Nothing deployed yet in NBL-101.
Action catalogue
GI-04Nutritional protocol
GI Support Protocol GI-04
symptom −31% · persistence +17% · onset 8 d
SC-12Supportive compound
Supportive Compound SC-12
symptom −18% · persistence +11% · onset 6 d
NP-02Nutritional protocol
Dietary Support Protocol NP-02
symptom −28% · persistence +9% · onset 10 d
HY-01Hydration protocol
Hydration Protocol HY-01
symptom −14% · persistence +6% · onset 4 d
ME-01Monitoring escalation
Monitoring Escalation ME-01
symptom −5% · persistence +12% · onset 3 d
BR-03Behavioural recommendation
Behavioural Recommendation BR-03
symptom −10% · persistence +10% · onset 7 d
CR-01Clinician review
Clinician Review CR-01
symptom −12% · persistence +15% · onset 5 d
AD-05Adherence support
Adherence Support AD-05
symptom −2% · persistence +14% · onset 5 d
DT-01Dosing / timing recommendation
Dosing / Timing Recommendation DT-01
symptom −16% · persistence +8% · onset 5 d